Fiji
Tuberculosis profile
Population  2013 <1 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.037 (0.036–0.037) 4.2 (4.1–4.2)
Mortality (HIV+TB only) <0.01 (<0.01–<0.01) 0.18 (0.07–0.33)
Prevalence  (includes HIV+TB) 0.88 (0.45–1.4) 100 (51–164)
Incidence  (includes HIV+TB) 0.5 (0.41–0.6) 57 (46–68)
Incidence (HIV+TB only) 0.011 (<0.01–0.015) 1.2 (0.84–1.7)
Case detection, all forms (%) 51 (42–62)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 0 (0–8.2) 0 (0–98)
MDR-TB cases among notified pulmonary
TB cases
0 (0–15) 0 (0–18)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 106   3
Pulmonary, clinically diagnosed 74   0
Extrapulmonary 71   0
       
Total new and relapse 254    
Previously treated, excluding relapses 15    
Total cases notified 269    
Among 254 new and relapse cases:
24 (9%) cases aged under 15 years; male:female ratio: 1.4
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 15 (14%) 3 (17%) 213
Laboratory-confirmed RR-/MDR-TB cases     0
Patients started on MDR-TB treatment     0
TB/HIV 2013 Number (%)
TB patients with known HIV status 186 (69)
HIV-positive TB patients 4 (2)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 4 (100)
HIV-positive TB patients on antiretroviral therapy (ART) 4 (100)
HIV-positive people screened for TB 43  
HIV-positive people provided with IPT 3  
Treatment success rate (%)
New and relapse cases registered in 2012 86
Previously treated cases, excluding relapse, registered in 2012 71
HIV-positive TB cases, all types, registered in 2012 100
RR-/MDR-TB cases started on second-line treatment in 2011  
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 0.5
Culture (per 5 million population) 5.7
Drug susceptibility testing (per 5 million population) 0
Sites performing Xpert MTB/RIF 3
Is second-line drug susceptibility testing available? No
Financing TB control 2014  
National TB programme budget (US$ millions) 2.4
% Funded domestically 54%
% Funded internationally 46%
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-07-29 Data: www.who.int/tb/data